![WuXi Biologics logo on a lit up phone screen [Credit: Piotr Swat/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/WuXi-Biologics-300x278.jpg)
![WuXi Biologics logo on a lit up phone screen [Credit: Piotr Swat/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/WuXi-Biologics.jpg)
WuXi announces record figures after successful year
Global biotechnology company WuXi has demonstrated the success of the CRDMO business model by publishing news of its bumper projects and revenues fuelled by innovative technology platforms in 2021.
List view / Grid view
News
Photo-responsive nanoassemblies could enable precision cancer drug delivery
Researchers demonstrate a simple system using photo-cleavable prodrugs for the precise delivery of cancer treatment in mice.
EMA human medicines committee (CHMP) meeting highlights, March 2022
The March meeting saw the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommend five medications for approval including a multiple myeloma gene therapy.
Jazz begins constructing new $100mn manufacturing site
The new manufacturing facility will support production and development of cannabis-based medicines in the UK.
Lab robotics market to value $494mn by 2030
Growing pharma and biotech R&D investments, and a drive to improve efficiency are driving growth in the global laboratory robotics market.
Novartis’ Pluvicto™ prostate cancer therapy approved by FDA
Novartis has received a boost to its arsenal of cancer therapeutics after the FDA approved Pluvicto™ and complementary diagnostic imaging agent Locametz® to treat advanced prostate cancer.
FDA releases draft guidance for cell and gene therapy industry
The US FDA has published two draft guidance documents, one on gene therapy products and the other CAR T-cell therapies, for developers and manufacturers.
![Merck logo atop Merck Research Laboratories campus in Silicon Valley [Credit: Michael Vi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Merck-5-300x278.jpg)
![Merck logo atop Merck Research Laboratories campus in Silicon Valley [Credit: Michael Vi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Merck-5-e1648202271156.jpg)
Dr Roy Baynes to retire from Merck
Dr Roy Baynes, Merck’s head of Global Clinical Development (GCD) and Chief Medical Officer, will retire in July.
Moderna launches two new mRNA vaccine programmes
The new mRNA vaccine programmes are aimed at the major causative agents of respiratory tract infections, respiratory syncytial virus (RSV), influenza and coronaviruses.
Lumen publishes details of spirulina biomanufacturing platform
In a new paper, Lumen Bioscience detailed how spirulina can be genetically engineered for to rapidly produce large quantities of biologic drugs.
VISIBLE aims to better understand experience of psoriasis for people of colour
Janssen has announced plans to initiate a large-scale study into the impact of psoriasis among black, Hispanic, Asian, indigenous and other people of colour.
Intravacc publishes GMP vaccine candidate manufacturing process
A new paper details the GMP manufacturing and formulation process for a semi-synthetic Shigella glycoconjugate vaccine candidate from Institut Pasteur.
Could ‘drug factory’ beads help combat cancer?
New pre-clinical testing shows interleukin producing ‘drug factory’ implants can eliminate ovarian and colorectal cancer in mice.
Novasep announces €5.1mn investment to grow HPAPI production
The €5.1 million will add a new chemical synthesis workshop for HPAPIs, expanding Novasep’s HPAPI production capacity at its Le Mans site in France.
New preventative medicine for COVID-19 authorised in UK
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has reported that Evusheld, developed by AstraZeneca, has been granted approval to help protect against the effects of COVID-19.
